Michael Krel

Michael Krel is a Partner at Sofinnova Partners focused on the firm's Industrial Biotech Strategy, primarily evaluating early-stage venture capital deals across the European market. He joined the European venture capital firm in 2013 to specialize in identifying, assessing, and executing early-stage investment opportunities within the broader industrial biotechnology sector. In his capacity as a specialized life sciences investor, Krel targets startups advancing novel industrial applications and prioritizes founding teams that demonstrate significant resilience and entrepreneurial grit. Over his continuous tenure of more than a decade at Sofinnova Partners, he has directly contributed to the firm's overarching mandate of funding early-stage sustainability and biotechnology enterprises. Ultimately, Krel maintains a dedicated current focus on deploying venture capital into emerging industrial biotechnology portfolio companies while actively supporting the long-term commercialization of European scientific research initiatives.